Insulin and neurodegenerative disease: Shared and specific mechanisms

Lancet Neurology

Volumn 3, Issue 3, 2004, Pages 169-178

  Craft, Suzanne ^a,b   Watson, G Stennis ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BROMOCRIPTINE; DOPAMINE; GAMMA SECRETASE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 8; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN RECEPTOR; LEVODOPA; PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; BLEEDING; CALCIUM TRANSPORT; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; GENE EXPRESSION; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM MEMORY; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANSPORT AND BINDING PHENOMENA; VERBAL MEMORY;

EID: 1242316296     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00681-7     Document Type: Review

References (143)

1. Rulifson E.J., Kim S.K., Nusse R. Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. Science. 296:2002;1118-1120.
2. Tatar M., Bartke A., Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 299:2003;1346-1351.
3. Schulingkamp R., Pagano T., Hung D., Raffa R. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev. 24:2000;855-872.
4. Ferrannini E., Galvan A.Q., Gastaldelli A., et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest. 29:1999;842-852.
5. Banks W.A., Jaspan J.B., Huang W., Kastin A.J. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides. 18:1997;1423-1429.
6. Banks W.A., Jaspan J.B., Kastin A.J. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides. 18:1997;1257-1262.
7. Baura G.D., Foster D.M., Porte D. Jr, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. J Clin Invest. 92:1993;1824-1830.
8. Baskin D., Figlewicz D., Woods S., Porte D., Dorsa D. Insulin in the brain. Annu Rev Physiol. 49:1987;335-347.
9. Wallum B.J., Taborsky G.J., Porte D., et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab. 64:1987;190-194.
10. Abbott M., Wells D., Fallon J. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci. 19:1999;7300-7308.
11. Havrankova J., Schmechel D., Roth J., Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci USA. 75:1978;5737-5741.
12. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 272:1978;827-829.
13. Unger J.W., Livingston J.N., Moss A.M. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol. 36:1991;343-362.
14. Lang A.E., Lozano A.M. Parkinson's disease: first of two parts. N Engl J Med. 339:1998;1044-1053.
15. Devaskar S.U., Giddings S.J., Rajakumar P.A., Carnaghi L.R., Menon R.K., Zahm D.S. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem. 269:1994;8445-8454.
16. Schechter R., Holtzclaw L., Sadiq F., Kahn A., Devaskar S. Insulin synthesis by isolated rabbit neurons. Endocrinology. 23:1988;505-513.
17. Singh B.S., Rajakumar P.A., Eves E.M., Rosner M.R., Wainer B.H., Devaskar S.U. Insulin gene expression in immortalized rat hippocampal and pheochromocytoma-12 cell lines. Regul Pept. 69:1997;7-14.
18. Park C.R., Seeley R.J., Craft S., Woods S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav. 68:2000;509-514.
19. Craft S., Asthana S., Newcomer J.W., et al. Enhancement of memory in Alzheimer's disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 56:1999;1135-1140.
20. Fehm H.L., Perras B., Smolnik R., Kern W., Born J. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharmacol. 405:2000;43-54.
21. Zhao W., Chen H., Xu H., et al. Brain insulin receptors and spatial memory: correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of the water maze trained rats. J Biol Chem. 274:1999;34893-34902.
22. Greenwood C., Winocur G. Glucose treatment reduces memory deficits in young rats fed high-fat diets. Neurobiol Learn Mem. 75:2001;179-189.
23. Marfaing-Jallat P., Portha B., Penicaud L. Altered conditioned taste aversion and glucose utilization in related brain nuclei of diabetic GK rats. Brain Res Bull. 37:1995;639-643.
24. Elias P.K., Elias M.F., D'Agostino R.B., et al. NIDDM and blood pressure as risk factors for poor cognitive performance: the Framingham Study. Diabetes Care. 20:1997;1388-1395.
25. Helkala E-L, Niskanen L., Viinamaki H., Partanen J., Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes Care. 18:1995;681-685.
26. Perlmuter L.C., Hakami M.K., Hodgson-Harrington C., et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med. 77:1984;1043-1048.
27. Strachan M.W., Deary I.J., Ewing F.M., Frier B.M. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care. 20:1997;438-445.
28. Vanhanen M., Kuusisto J., Koivisto K., et al. Type-2 diabetes and cognitive function in a non-demented population. Acta Neurol Scand. 100:1999;97-101.
29. Vanhanen M., Koivisto K., Kuusisto J., et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care. 21:1998;398-402.
30. Doyle P., Cusin I., Rohner-Jeanrenaud F., Jeanrenaud B. Four-day hyperinsulinemia in euglycemic conditions alters local cerebral glucose utilization in specific brain nuclei of freely moving rats. Brain Res. 684:1995;47-55.
31. Lucignani G., Namba H., Nehlig A., Porrino L., Kennedy C., Sokoloff L. Effects of insulin on local cerebral glucose utilization in the rat. J Cereb Blood Flow Metab. 7:1987;309-314.
32. Marfaing P., Penicaud L., Broer Y., Mraovitch S., Calando Y., Picon L. Effects of hyperinsulinemia on local cerebral insulin binding and glucose utilization in normoglycemic awake rats. Neurosci Lett. 115:1990;279-285.
33. Fanelli C., Dence C., Markham J., et al. Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes. Diabetes. 47:1998;1444-1450.
34. Hasselbalch S., Knudsen G., Videback C., et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes. 48:1999;1915-1921.
35. Bingham E.M., Hopkins D., Smith D., et al. The role of insulin in human brain glucose metabolism: an 18-fluoro-deoxyglucose positron emission tomography study. Diabetes. 51:2002;3384-3390.
36. Apelt J., Mehlhorn G., Schliebs R. Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res. 57:1999;693-705.
37. Brant A., Jess T., Milligan G., Brown C., Gould G. Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem Biophys Res Commun. 192:1993;1297-1302.
38. El-Messari S., Leloup C., Quignon M., Brisorgueil M.J., Penicaud L., Arluison M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J Comp Neurol. 399:1998;492-512.
39. Livingstone C., Lyall H., Gould G. Hypothalamic GLUT 4 expression: a glucose- and insulin-sensing mechanism? Mol Cell Endocrinol. 107:1995;67-70.
40. Ibberson M., Uldry M., Thorens B. GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J Biol Chem. 275:2000;4607-4612.
41. Reagan L., Gorovits N., Hoskin E., et al. Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc Natl Acad Sci USA. 98:2001;2820-2825.
42. Zhao W-T, Alkon D.L. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 177:2001;125-134.
43. Skeberdis V., Lan J-y, Zheng X., Zuklin R., Bennett M. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA. 98:2001;3561-3566.
44. Kopf S., Baratti C. Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem. 71:1999;50-61.
45. Figlewicz D.P., Szot P., Israel P.A., Payne C., Dorsa D.M. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 602:1993;161-164.
46. Craft S., Newcomer J., Kanne S., et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 17:1996;123-130.
47. Chui H., Mack W., Jackson J., et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 57:2000;191-196.
48. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 21:2000;321-330.
49. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 21:1998;518-524.
50. Gregg E.W., Yaffe K., Cauley J.A., et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch Intern Med. 160:2000;174-180.
51. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 39:1996;1392-1397.
52. Leibson C.L., Rocca W.A., Hanson V.A., et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 145:1997;301-308.
53. Brayne C., Gill C., Huppert F. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord. 9:1998;175-180.
54. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 10:1999;1937-1942.
55. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol (in press).
56. Curb J.D., Rodriguez B.L., Abbott R.D., et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 52:1999;971-975.
57. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 51:2002;1256-1262.
58. Kuusisto J., Koivisto K., Mykkanen L., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 315:1997;1045-1049.
59. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer's disease. First Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG 2003). Gothenborg, Sweden, 2003.
60. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., Fehm H. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 74:2001;270-280.
61. Craft S., Asthana S., Schellenberg G.D., et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology. 70:1999;146-152.
62. Hoyer S. The aging brain: changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). J Neural Transm. 109:2002;991-1002.
63. Frolich L., Blum-Degen D., Bernstein H.G., et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm. 105:1998;423-438.
64. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50:1998;164-168.
65. Fujisawa Y., Sasaki K., Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry. 30:1991;1219-1228.
66. Gasparini L., Gouras G.K., Wang R., et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 21:2001;2561-2570.
67. Authier F., Posner B.I., Bergeron JJM. Insulin-degrading enzyme. Clin Invest Med. 19:1996;149-160.
68. Kurochkin I.V., Goto S. Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345:1994;33-37.
69. McDermott J.R., Gibson A.M. Degradation of Alzheimer's β-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res. 22:1997;49-56.
70. Qiu W.Q., Walsh D.M., Ye Z., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem. 273:1998;32730-32738.
71. Sudoh S., Frosch M.P., Wolf B.A. Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and insoluble pools in CHO-695 cells. Biochemistry (Mosc). 41:2002;1091-1099.
72. Edbauer D., Willem M., Lammich S., Steiner H., Haass C. Insulin-degrading enzyme rapidly removes the β-amyloid precursor protein intracellular domain (AICD). J Biol Chem. 277:2002;279-288.
73. Perez A., Morelli L., Cresto J.C., Castano E.M. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res. 25:2000;247-255.
74. Cook D.G., Leverenz J.B., McMillan P.J., et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol. 162:2003;313-319.
75. Farris W., Mansourian S., Chang Y., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 100:2003;4162-4167.
76. Ho L, Qin W, Pompl PL, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (in press).
77. Watson G.S., Peskind E.R., Asthana S., et al. Insulin Increases CSF Aβ42 levels in normal older adults. Neurology. 60:2003;1899-1903.
78. Tong L., Thornton P.L., Balazs R., Cotman C.W. amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem. 276:2001;17301-17306.
79. Westerman M., Cooper-Blacketer D., Mariash A. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 22:2002;1858-1867.
80. Wang H.W., Pasternak J.F., Kuo H., et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924:2002;133-140.
81. Schwartz M.W., Figlewicz D.F., Kahn S.E., Baskin D.G., Greenwood M.R., Porte D.J. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides. 11:1990;467-472.
82. Gerozissis K., Orosco M., Rouch C., Nicolaidis S. Basal and hyperinsulinemia-induced immunoreactive hypothalamic insulin changes in lean and genetically obese Zucker rats revealed by microdialysis. Brain Res. 611:1993;258-263.
83. Oddo S., Caccamo A., Shepherd J.D., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 39:2003;409-421.
84. Hong M., Lee V. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 272:1997;19547-19553.
85. Schubert M., Brazil D.P., Burks D.J., et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 23:2003;7084-7092.
86. McGeer P.L., McGeer E.G. Inflamation, autotoxicity and Alzheimer's disease. Neurobiol Aging. 22:2001;799-809.
87. Dandona P. Endothelium, inflammation, and diabetes. Curr Diab Rep. 2:2002;311-315.
88. Facchini F.S., Hua N.W., Reaven G.M., Stoohs R.A. Hyperinsulinemia: the missing link among oxidative stress and age-related disease? Free Radic Biol Med. 29:2000;1302-1306.
89. Axelrod L. Insulin, prostaglandins, and the pathogenesis of hypertension. Diabetes. 40:1991;1223-1227.
90. Laight D., Desai K., Gopul N. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur J Pharmacol. 377:1999;89-92.
91. Soop M., Duxbury H., Agwunobi A. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab. 282:2002;E1276-1285.
92. Liolitsa D., Powell J., Lovestone S. Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 73:2002;261-266.
93. Bertram L., Blacker D., Mullin K., et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 290:2000;2302-2303.
94. Ait-Ghezala G., Abdullah L., Crescentini R., et al. Confirmation of association between D10S583 and Alzheimer's disease in a case-control sample. Neurosci Lett. 325:2002;87-90.
95. Boussaha M., Hannequin D., Verpillat B., Frebourg T., Campior D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett. 329:2002;121-123.
96. Abraham R., Myers A., Wayrant-DeVrieze F. Substanial linkage disequilibrium across the insulin degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet. 109:2001;646-652.
97. Myers A., Holmans P., Marshal H., et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 290:2000;2304-2305.
98. Ertekin-Taner N., Graff-Radford N., Younkin L.H., et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 290:2000;2303-2304.
99. Edland S.D., Wavrant-De Vriese F., Compton D., et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett. 345:2003;21-24.
100. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 277:2002;39684-39695.
101. Dupont J., LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res. 55:(suppl 2):2001;22-26.
102. Kim J.J., Accili D. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res. 12:2002;84-90.
103. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat Med. 8:2002;1390-1397.
104. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26:2003;404-406.
105. Nestler J.E., Barlascini C.O., Tetrault G.A., Fratkin M.J., Clore J.N., Blackard W.G. Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia. Diabetes. 39:1990;1212-1217.
106. Wheatcroft S.B., Williams I.L., Shah A.M., Kearney M.T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 20:2003;255-268.
107. Baird T., Parsons M., Barber P., et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci. 9:2002;618-626.
108. Meigs J. Epidemiology of the insulin resistance syndrome. Curr Diab Rep. 3:2003;73-79.
109. Kuusisto J., Koivisto K., Mykkanen L., et al. Essential hypertension and cognitive function: the role of hyperinsulinaemia. Hypertension. 22:1993;771-779.
110. Meyer J.S., McClintic K.L., Rogers R.L., Sims P., Mortel K.F. Aetiological considerations and risk factors for multi-infarct dementia. J Neurol Neurosurg Psychiatry. 51:1988;1489-1497.
111. Ross G.W., Petrovitch H., White L.R., et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology. 53:1999;337-343.
112. Haan M.N., Mungas D.M., Gonzalez H.M., Ortiz T.A., Acharya A., Jagust W.J. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc. 51:2003;169-177.
113. Carantoni M., Zuliani G., Munari M.R., D'Elia K., Palmieri E., Fellin R. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement Geriatr Cogn Disord. 11:2000;176-180.
114. Hassing L.B., Johansson B., Nilsson S.E., et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr. 14:2002;239-248.
115. Kernan W., Inzucchi S., Viscoli C., Brass L., Bravata D., Horwitz R. Insulin resistance and risk for stroke. Neurology. 59:2002;809-815.
116. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 69:1993;125-130.
117. Pressley J.C., Louis E.D., Tang M.X., et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 60:2003;87-93.
118. Van Woert M.H., Mueller P.S. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clin Pharmacol Ther. 12:1971;360-367.
119. Sirtori C.R., Bolme P., Azarnoff D.L. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med. 287:1972;729-733.
120. Boyd AE III, Lebovitz H.E., Feldman J.M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa. J Clin Endocrinol Metab. 33:1971;829-837.
121. Lipman I.J., Boykin M.E., Flora R.E. Glucose intolerance in Parkinson's disease. J Chronic Dis. 27:1974;573-579.
122. Demirkiran M., Bozdemir H., Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 104:2001;63-67.
123. Foltynie T., Barker R., Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology. 21:2002;1-7.
124. Jellinger K.A. Prevalence of cerebrovascular lesions in Parkinson's disease: a postmortem study. Acta Neuropathol (Berl). 105:2003;415-419.
125. Schwab R.S. Progession and prognosis in Parkinson's disease. J Nerv Ment Dis. 130:1960;556-566.
126. Sandyk R., Awerbuch G.I. The association of diabetes mellitus with dementia in Parkinson's disease. Int J Neurosci. 64:1992;209-212.
127. Salgnik I., Korczyn A. Risk factors for dementia in Parkinson's disease. Adv Neurol. 53:1990;343-347.
128. Levy G., Tang M.X., Cote L.J., et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord. 17:2002;250-257.
129. Moroo I., Yamada T., Makino H., et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol (Berl). 87:1994;343-348.
130. Takahashi M., Yamada T., Tooyama I., et al. Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci Lett. 204:1996;201-204.
131. Jimenez-Jimenez F.J., Molina J.A., Vargas C., et al. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J Neural Transm. 107:2000;445-449.
132. Luo S., Liang Y., Cincotta A.H. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology. 69:1999;160-166.
133. Figlewicz D.P., Szot P., Chavez M., Woods S.C., Veith R.C. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res. 644:1994;331-334.
134. Liu Z., Wang Y., Zhao W., et al. Peptide derived from insulin with regulatory activity of dopamine transporter. Neuropharmacology. 41:2001;464-471.
135. Figlewicz D.P., Brot M.D., McCall A.L., Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res. 736:1996;54-60.
136. Murzi E., Contreras Q., Teneud L., et al. Diabetes decreases limbic extracellular dopamine in rats. Neurosci Lett. 202:1996;141-144.
137. Lozovsky D., Saller C.F., Kopin I.J. Dopamine receptor binding is increased in diabetic rats. Science. 214:1981;1031-1033.
138. Podolsky S., Leopold N.A. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology. 23:1977;55-63.
139. Farrer L.A. Diabetes mellitus in Huntington disease. Clin Genet. 27:1985;62-67.
140. Schobotz R., Hausmann L., Kaffarnik H., Zehner J., Oepen H. Fatty acid patterns and glucose tolerance in Huntington's chorea. Res Exp Med (Berl). 167:1976;203-215.
141. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes. 48:1999;649-651.
142. Andreassen O.A., Dedeoglu A., Stanojevic V., et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis. 11:2002;410-424.
143. Thomas E., Foye P., Alvarez C., Usui H., Stucliffe J. Insulin receptor substrate protein p53 localization in rats suggests mechanism for specific polyglutamine neurodegeneration. Neurosci Lett. 309:2001;145-148.